Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Elizabeth L. et al. (2017) DOI: 10.1200/JCO.2016.70.4627 
30 plasma (blood) and tumor samples obtained
Group I: Patients w...
Upcoming SlideShare
Loading in …5

Medical diagnostics


Published on

Medical diagnostics

Published in: Science
  • Be the first to comment

  • Be the first to like this

Medical diagnostics

  1. 1. Elizabeth L. et al. (2017) DOI: 10.1200/JCO.2016.70.4627  30 plasma (blood) and tumor samples obtained Group I: Patients with history of malignancy before diagnosis of HGSC Group II: Patients with recurrent HGSC - performed using primers flanking BRCA1/2 mutations - primer design not based on prior knowledge of reversion sequences - reversions analyzed in both tumor and plasma samples - results subsequently matched to understand significance of cf-DNA liquid biopsy in identifying BRCA1/2 mutations and reversions - BRCA1/2 mutations found in all analyzed tumor samples - reversions found in only 4 tumor samples from group II Targeted Amplicon Sequencing Chemotherapy with platins and poly-ADP ribose polymerase inhibitor-based drugs is ineffective in patients with BRCA1/2 reversion mutations Liquid Biopsy Targeted Amplicon Sequencing Patients with BRCA1/2 reversions in tumor samples Positive predictive value = 1 Negative predictive value = 0.9 PatientswithBRCA1/2 reversionsinplasmasamples Positive Positive Negative Negative True positive False positive True negativeFalse negative 4 0 242 Patients with BCRA1/2 reversions Emergence of drug resistance and relapse Chemotherapy Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer Predicting Therapeutic Outcome in High-Grade Serous Ovarian Cancer by Circulating DNA Analysis Chemotherapy response in patients with HGSC can be predicted using a noninvasive liquid biopsy - mutations favor response to chemtherapy - reversions could result in chemoresistance Cell-Free DNA (cf-DNA) - freely circulating molecules in blood - contain DNA of tumor origin Liquid Biopsy - can analyze BRCA1/2 mutations in cf-DNA samples - can predict treatment outcome if successful BRCA1/2 mutations & reversions 30 patients with HGSC with BRCA1/2 mutations HGSC = High-Grade Serous Ovarian Cancer Background Methodology Results Outcome  | /ASCOCancer  | @ASCO